pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog
The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in...
Gespeichert in:
| Veröffentlicht in: | Journal of veterinary pharmacology and therapeutics 2014-06, Vol.37 (3), p.279-285 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 285 |
|---|---|
| container_issue | 3 |
| container_start_page | 279 |
| container_title | Journal of veterinary pharmacology and therapeutics |
| container_volume | 37 |
| creator | Collard, W. T Hummel, B. D Fielder, A. F King, V. L Boucher, J. F Mullins, M. A Malpas, P. B Stegemann, M. R |
| description | The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in a crossover study in beagles and mongrels dogs. Dose proportionality and multiple dose pharmacokinetics were evaluated in a parallel design study with eight dogs per group. In all four studies, serial blood samples for plasma were collected. Oclacitinib maleate was rapidly and well absorbed following oral administration, with a time to peak plasma concentration of |
| doi_str_mv | 10.1111/jvp.12087 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1522680508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1522680508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3877-6456e803b0ec0aefe9515d4e4a1b772ba288fefd43be8d5a599c8b14d1000bb23</originalsourceid><addsrcrecordid>eNp1kVFPFDEQxxsjkRN98AtoHzVhod1ut71HQgQ9DjUomvjSTLuzXGF3e7R7Kt_ewgJvzMvMJL_5Z-Y_hLzhbI_n2L_8s97jJdPqGZlxUcui1Fo-JzPGK1YopcU2eZnSJWNMaM5fkO2yEiI3fEZO1yuIPbhw5QccvUs0tDS4Dpwf_eAt7aFDGHGXAl3AsEk0g5CQ-mHlrR9D3M0lHVdIm3Dximy10CV8fZ93yPnRxx-Hn4rl1-PPhwfLwgmtVFFXskbNhGXoGGCLc8llU2EF3CpVWsj7t9g2lbCoGwlyPnfa8qrh-QRrS7FD3k-66xiuN5hG0_vksOtgwLBJhsuyrDWTTGf0w4S6GFKK2Jp19D3EG8OZuXXPZPfMnXuZfXsvu7E9No_kg10Z2J-Av77Dm6eVzOLntwfJYprwacR_jxMQr0ythJLm15djc6LPzn4vlsKcZP7dxLcQDFxEn8z59_L2kSwfI2st_gN3IZEo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1522680508</pqid></control><display><type>article</type><title>pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Collard, W. T ; Hummel, B. D ; Fielder, A. F ; King, V. L ; Boucher, J. F ; Mullins, M. A ; Malpas, P. B ; Stegemann, M. R</creator><creatorcontrib>Collard, W. T ; Hummel, B. D ; Fielder, A. F ; King, V. L ; Boucher, J. F ; Mullins, M. A ; Malpas, P. B ; Stegemann, M. R</creatorcontrib><description>The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in a crossover study in beagles and mongrels dogs. Dose proportionality and multiple dose pharmacokinetics were evaluated in a parallel design study with eight dogs per group. In all four studies, serial blood samples for plasma were collected. Oclacitinib maleate was rapidly and well absorbed following oral administration, with a time to peak plasma concentration of <1 h and an absolute bioavailability of 89%. The prandial state of dogs did not significantly affect the rate or extent of absorption of oclacitinib maleate when dosed orally, as demonstrated by the lack of significant differences in pharmacokinetic parameters between the oral fasted and oral fed treatment groups. The pharmacokinetics of oclacitinib in laboratory populations of beagles and mixed breed dogs also appeared similar. Following oral administration, the exposure of oclacitinib maleate increased dose proportionally from 0.6 to 3.0 mg/kg. Additionally, across the pharmacokinetic studies, there were no apparent differences in oclacitinib pharmacokinetics attributable to sex.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/jvp.12087</identifier><identifier>PMID: 24330031</identifier><language>eng</language><publisher>England: Blackwell Science</publisher><subject>absorption ; Animals ; Area Under Curve ; Beagle ; bioavailability ; Biological Availability ; blood ; Cross-Over Studies ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - pharmacokinetics ; dogs ; Dogs - blood ; Dogs - metabolism ; experimental design ; Female ; Half-Life ; Male ; maleates ; non-specific protein-tyrosine kinase ; oral administration ; pharmacokinetics ; Pyrimidines - administration & dosage ; Pyrimidines - pharmacokinetics ; Sulfonamides - administration & dosage ; Sulfonamides - pharmacokinetics</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2014-06, Vol.37 (3), p.279-285</ispartof><rights>2013 John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3877-6456e803b0ec0aefe9515d4e4a1b772ba288fefd43be8d5a599c8b14d1000bb23</citedby><cites>FETCH-LOGICAL-c3877-6456e803b0ec0aefe9515d4e4a1b772ba288fefd43be8d5a599c8b14d1000bb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvp.12087$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvp.12087$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24330031$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Collard, W. T</creatorcontrib><creatorcontrib>Hummel, B. D</creatorcontrib><creatorcontrib>Fielder, A. F</creatorcontrib><creatorcontrib>King, V. L</creatorcontrib><creatorcontrib>Boucher, J. F</creatorcontrib><creatorcontrib>Mullins, M. A</creatorcontrib><creatorcontrib>Malpas, P. B</creatorcontrib><creatorcontrib>Stegemann, M. R</creatorcontrib><title>pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J. vet. Pharmacol. Therap</addtitle><description>The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in a crossover study in beagles and mongrels dogs. Dose proportionality and multiple dose pharmacokinetics were evaluated in a parallel design study with eight dogs per group. In all four studies, serial blood samples for plasma were collected. Oclacitinib maleate was rapidly and well absorbed following oral administration, with a time to peak plasma concentration of <1 h and an absolute bioavailability of 89%. The prandial state of dogs did not significantly affect the rate or extent of absorption of oclacitinib maleate when dosed orally, as demonstrated by the lack of significant differences in pharmacokinetic parameters between the oral fasted and oral fed treatment groups. The pharmacokinetics of oclacitinib in laboratory populations of beagles and mixed breed dogs also appeared similar. Following oral administration, the exposure of oclacitinib maleate increased dose proportionally from 0.6 to 3.0 mg/kg. Additionally, across the pharmacokinetic studies, there were no apparent differences in oclacitinib pharmacokinetics attributable to sex.</description><subject>absorption</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>Beagle</subject><subject>bioavailability</subject><subject>Biological Availability</subject><subject>blood</subject><subject>Cross-Over Studies</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - pharmacokinetics</subject><subject>dogs</subject><subject>Dogs - blood</subject><subject>Dogs - metabolism</subject><subject>experimental design</subject><subject>Female</subject><subject>Half-Life</subject><subject>Male</subject><subject>maleates</subject><subject>non-specific protein-tyrosine kinase</subject><subject>oral administration</subject><subject>pharmacokinetics</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - pharmacokinetics</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - pharmacokinetics</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kVFPFDEQxxsjkRN98AtoHzVhod1ut71HQgQ9DjUomvjSTLuzXGF3e7R7Kt_ewgJvzMvMJL_5Z-Y_hLzhbI_n2L_8s97jJdPqGZlxUcui1Fo-JzPGK1YopcU2eZnSJWNMaM5fkO2yEiI3fEZO1yuIPbhw5QccvUs0tDS4Dpwf_eAt7aFDGHGXAl3AsEk0g5CQ-mHlrR9D3M0lHVdIm3Dximy10CV8fZ93yPnRxx-Hn4rl1-PPhwfLwgmtVFFXskbNhGXoGGCLc8llU2EF3CpVWsj7t9g2lbCoGwlyPnfa8qrh-QRrS7FD3k-66xiuN5hG0_vksOtgwLBJhsuyrDWTTGf0w4S6GFKK2Jp19D3EG8OZuXXPZPfMnXuZfXsvu7E9No_kg10Z2J-Av77Dm6eVzOLntwfJYprwacR_jxMQr0ythJLm15djc6LPzn4vlsKcZP7dxLcQDFxEn8z59_L2kSwfI2st_gN3IZEo</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Collard, W. T</creator><creator>Hummel, B. D</creator><creator>Fielder, A. F</creator><creator>King, V. L</creator><creator>Boucher, J. F</creator><creator>Mullins, M. A</creator><creator>Malpas, P. B</creator><creator>Stegemann, M. R</creator><general>Blackwell Science</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201406</creationdate><title>pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog</title><author>Collard, W. T ; Hummel, B. D ; Fielder, A. F ; King, V. L ; Boucher, J. F ; Mullins, M. A ; Malpas, P. B ; Stegemann, M. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3877-6456e803b0ec0aefe9515d4e4a1b772ba288fefd43be8d5a599c8b14d1000bb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>absorption</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>Beagle</topic><topic>bioavailability</topic><topic>Biological Availability</topic><topic>blood</topic><topic>Cross-Over Studies</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - pharmacokinetics</topic><topic>dogs</topic><topic>Dogs - blood</topic><topic>Dogs - metabolism</topic><topic>experimental design</topic><topic>Female</topic><topic>Half-Life</topic><topic>Male</topic><topic>maleates</topic><topic>non-specific protein-tyrosine kinase</topic><topic>oral administration</topic><topic>pharmacokinetics</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - pharmacokinetics</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collard, W. T</creatorcontrib><creatorcontrib>Hummel, B. D</creatorcontrib><creatorcontrib>Fielder, A. F</creatorcontrib><creatorcontrib>King, V. L</creatorcontrib><creatorcontrib>Boucher, J. F</creatorcontrib><creatorcontrib>Mullins, M. A</creatorcontrib><creatorcontrib>Malpas, P. B</creatorcontrib><creatorcontrib>Stegemann, M. R</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collard, W. T</au><au>Hummel, B. D</au><au>Fielder, A. F</au><au>King, V. L</au><au>Boucher, J. F</au><au>Mullins, M. A</au><au>Malpas, P. B</au><au>Stegemann, M. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J. vet. Pharmacol. Therap</addtitle><date>2014-06</date><risdate>2014</risdate><volume>37</volume><issue>3</issue><spage>279</spage><epage>285</epage><pages>279-285</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in a crossover study in beagles and mongrels dogs. Dose proportionality and multiple dose pharmacokinetics were evaluated in a parallel design study with eight dogs per group. In all four studies, serial blood samples for plasma were collected. Oclacitinib maleate was rapidly and well absorbed following oral administration, with a time to peak plasma concentration of <1 h and an absolute bioavailability of 89%. The prandial state of dogs did not significantly affect the rate or extent of absorption of oclacitinib maleate when dosed orally, as demonstrated by the lack of significant differences in pharmacokinetic parameters between the oral fasted and oral fed treatment groups. The pharmacokinetics of oclacitinib in laboratory populations of beagles and mixed breed dogs also appeared similar. Following oral administration, the exposure of oclacitinib maleate increased dose proportionally from 0.6 to 3.0 mg/kg. Additionally, across the pharmacokinetic studies, there were no apparent differences in oclacitinib pharmacokinetics attributable to sex.</abstract><cop>England</cop><pub>Blackwell Science</pub><pmid>24330031</pmid><doi>10.1111/jvp.12087</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-7783 |
| ispartof | Journal of veterinary pharmacology and therapeutics, 2014-06, Vol.37 (3), p.279-285 |
| issn | 0140-7783 1365-2885 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1522680508 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | absorption Animals Area Under Curve Beagle bioavailability Biological Availability blood Cross-Over Studies Dermatologic Agents - administration & dosage Dermatologic Agents - pharmacokinetics dogs Dogs - blood Dogs - metabolism experimental design Female Half-Life Male maleates non-specific protein-tyrosine kinase oral administration pharmacokinetics Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Sulfonamides - administration & dosage Sulfonamides - pharmacokinetics |
| title | pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A46%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=pharmacokinetics%20of%20oclacitinib%20maleate,%20a%20Janus%20kinase%20inhibitor,%20in%20the%20dog&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=Collard,%20W.%20T&rft.date=2014-06&rft.volume=37&rft.issue=3&rft.spage=279&rft.epage=285&rft.pages=279-285&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/jvp.12087&rft_dat=%3Cproquest_cross%3E1522680508%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1522680508&rft_id=info:pmid/24330031&rfr_iscdi=true |